Cristóbal Lecaros
Cristóbal Lecaros has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Raúl Cabrera
Department of Dermatology, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
4 shared publications - Francisca Reculé
Department of Dermatology, Faculty of Medicine Clínica Alemana—Universidad del Desarrollo Santiago Chile
3 shared publications - Alex Castro
Pathology Department, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile
2 shared publications - Christopher Ernest Maitland Griffiths
Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre University of Manchester Manchester UK
2 shared publications - Constanza Del Puerto
Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
2 shared publications - Edinson López
Clínica Alemana – Universidad del Desarrollo
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Experiência clínica com deucravacitinibe em pacientes com psoríase: a perspectiva chilena
- 19 February 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Open AccessExperiência clínica com deucravacitinibe em pacientes com psoríase: a perspectiva chilena
- Open Access
- 4 September 2025
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 152 (10) , 1064-1069
Comparison of two techniques for measuring Demodex folliculorum and Demodex brevis in rosacea patients: standardized skin surface biopsy vs. direct microscopic examination
Rosacea is a chronic inflammatory skin disease affecting approximately 5.4% of the world population. Among its pathogenic factors is infestation by Demodex spp. Standardized skin surface biopsy (SSSB) and direct microscopic examination (DME) are widely used methods to measure Demodex spp density (Dd); however, there is no agreement on the method of choice, nor the prevalence of infestation in rosacea patients. This study compared both techniques in rosacea patients. A prospective study was conducted with 61 patients diagnosed with rosacea by dermatologists from two dermatology centres. Dd was evaluated using SSSB and DME in each patient. Results, median sampling time and reported pain were analyzed using appropriate statistical methods. The median Dd was significantly higher with SSSB (11 mites/cm 2 ) compared to DME (1 mites/cm 2 ; P < 0.001). Infestation (>5 mites/cm 2 ) was detected in 64% of patients with SSSB and in 28% with DME ( P < 0.001). The median sampling time was longer for SSSB (60 s) than for DME (30 s; P < 0.001). Both methods were associated with mild pain, slightly lower with DME ( P = 0.033). SSSB proved more effective than DME for detecting Demodex spp. in rosacea, identifying a greater total number of mites and a higher percentage of infestation. Up to 64% of rosacea patients showed infestation with Demodex spp. using the SSSB technique. The results reinforce the use of SSSB as the standard technique for diagnosing Demodex spp. infestation in rosacea patients.
- 4 September 2025
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 152 (10) , 1064-1069
Open AccessComparison of two techniques for measuring Demodex folliculorum and Demodex brevis in rosacea patients: standardized skin surface biopsy vs. direct microscopic examination
Rosacea is a chronic inflammatory skin disease affecting approximately 5.4% of the world population. Among its pathogenic factors is infestation by Demodex spp. Standardized skin surface biopsy (SSSB) and direct microscopic examination (DME) are widely used methods to measure Demodex spp density (Dd); however, there is no agreement on the method of choice, nor the prevalence of infestation in rosacea patients. This study compared both techniques in rosacea patients. A prospective study was conducted with 61 patients diagnosed with rosacea by dermatologists from two dermatology centres. Dd was evaluated using SSSB and DME in each patient. Results, median sampling time and reported pain were analyzed using appropriate statistical methods. The median Dd was significantly higher with SSSB (11 mites/cm 2 ) compared to DME (1 mites/cm 2 ; P < 0.001). Infestation (>5 mites/cm 2 ) was detected in 64% of patients with SSSB and in 28% with DME ( P < 0.001). The median sampling time was longer for SSSB (60 s) than for DME (30 s; P < 0.001). Both methods were associated with mild pain, slightly lower with DME ( P = 0.033). SSSB proved more effective than DME for detecting Demodex spp. in rosacea, identifying a greater total number of mites and a higher percentage of infestation. Up to 64% of rosacea patients showed infestation with Demodex spp. using the SSSB technique. The results reinforce the use of SSSB as the standard technique for diagnosing Demodex spp. infestation in rosacea patients.
- 17 August 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7) , e481-e485
Dermoscopic Findings in Linear Acral Melanocytic Nevi: Case Series and Literature Review
- 17 August 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7) , e481-e485
Dermoscopic Findings in Linear Acral Melanocytic Nevi: Case Series and Literature Review
- Open Access
- 1 September 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (5) , 780-783
Resposta inadequada à terapia antiplaquetária na síndrome de Sneddon. É hora de reavaliar as recomendações de manejo?
- 1 September 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (5) , 780-783
Open AccessResposta inadequada à terapia antiplaquetária na síndrome de Sneddon. É hora de reavaliar as recomendações de manejo?
- Open Access
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 546-567
Terapia direcionada para doenças imunomediadas da pele. O que o dermatologista deve saber?
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 546-567
Open AccessTerapia direcionada para doenças imunomediadas da pele. O que o dermatologista deve saber?
- 11 June 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (5) , 835-837
Epidemiology of epidermolysis bullosa in Chile
In this manuscript we are presenting the first National Epidermolysis Bullosa Epidemiology study done in South America. Our manuscript describes not only population-level estimates, such as incidence, prevalence and mortality of EB, but also genetic data that are unique to this underrepresented population. We report new data about this rare disease showing comparable life expectancy to wealthier nations, demonstrating the value of specialized EB care centres.
- 11 June 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (5) , 835-837
Epidemiology of epidermolysis bullosa in Chile
In this manuscript we are presenting the first National Epidermolysis Bullosa Epidemiology study done in South America. Our manuscript describes not only population-level estimates, such as incidence, prevalence and mortality of EB, but also genetic data that are unique to this underrepresented population. We report new data about this rare disease showing comparable life expectancy to wealthier nations, demonstrating the value of specialized EB care centres.
- Open Access
- 23 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (5) , 780-783
Inadequate response to antiplatelet therapy in Sneddon's syndrome. Time to re-evaluate management recommendations?
- 23 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (5) , 780-783
Open AccessInadequate response to antiplatelet therapy in Sneddon's syndrome. Time to re-evaluate management recommendations?
- Open Access
- 22 March 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 546-567
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
- 22 March 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 546-567
Open AccessTargeted therapy for immune mediated skin diseases. What should a dermatologist know?
- Open Access
- 1 December 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (12) , 2234-2241
Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
Background: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America.Aim: To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis.Methods: This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression.Results: In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 ± 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 ± 11.5; body surface area 14.7 ± 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis.Conclusions: We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.
- 1 December 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (12) , 2234-2241
Open AccessComorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
Background: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America.Aim: To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis.Methods: This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression.Results: In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 ± 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 ± 11.5; body surface area 14.7 ± 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis.Conclusions: We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.
- Open Access
- 29 April 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (7) , 1262-1269
The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository
Summary: Background: Psoriasis is a serious and chronic noncommunicable disease. However, the fundamental measure of disease occurrence, the incidence, has been scarcely reported globally. There are no previous studies of psoriasis incidence in Latin America. Aim: To estimate the incidence rates of psoriasis in Chile during 2016 and 2017 using an administrative database, the Waiting List Repository. Methods: We examined referrals of psoriasis at onset, made by physicians to dermatologists, evaluated the agreement of diagnosis, and estimated the incidence of the disease considering the eligible population at risk. Results: In most cases, the referrals corresponded to incident cases of psoriasis (73.3%; 95% CI: 66.6–79.2). The national incidence rates of psoriasis were 22.1 (95% CI: 21.1–23.1) and 22.7 (95% CI: 21.8–23.6) per 100 000 person-years in 2016 and 2017, respectively. The most common type of psoriasis was the late-onset type. We observed a high variation in the figures throughout the country, with a range from 0.75 (95% CI: 0.3–1.5) per 100 000 person-years in the Metropolitan region to 164.9 (95% CI: 138.6–195.1) per 100 000 person-years in the Aysen region. Conclusion: We describe for the first time the incidence of psoriasis in a Latin American country. Our findings could potentially guide collaborations to improve our global understanding of psoriasis in Latin America.
- 29 April 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (7) , 1262-1269
Open AccessThe incidence of psoriasis in Chile: an analysis of the National Waiting List Repository
Summary: Background: Psoriasis is a serious and chronic noncommunicable disease. However, the fundamental measure of disease occurrence, the incidence, has been scarcely reported globally. There are no previous studies of psoriasis incidence in Latin America. Aim: To estimate the incidence rates of psoriasis in Chile during 2016 and 2017 using an administrative database, the Waiting List Repository. Methods: We examined referrals of psoriasis at onset, made by physicians to dermatologists, evaluated the agreement of diagnosis, and estimated the incidence of the disease considering the eligible population at risk. Results: In most cases, the referrals corresponded to incident cases of psoriasis (73.3%; 95% CI: 66.6–79.2). The national incidence rates of psoriasis were 22.1 (95% CI: 21.1–23.1) and 22.7 (95% CI: 21.8–23.6) per 100 000 person-years in 2016 and 2017, respectively. The most common type of psoriasis was the late-onset type. We observed a high variation in the figures throughout the country, with a range from 0.75 (95% CI: 0.3–1.5) per 100 000 person-years in the Metropolitan region to 164.9 (95% CI: 138.6–195.1) per 100 000 person-years in the Aysen region. Conclusion: We describe for the first time the incidence of psoriasis in a Latin American country. Our findings could potentially guide collaborations to improve our global understanding of psoriasis in Latin America.